Benzinga | Jul 15, 2021 08:36AM EDT

AMMO Announces The European Medicines Agency Has Validated Co.'s Marketing Authorization Application For Valoctocogene Roxaparvovec

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that the European Medicines Agency (EMA) validated the Company's Marketing Authorization Application (MAA) for its investigational gene therapy, valoctocogene roxaparvovec, for adults with severe hemophilia A. With today's validation the MAA review can now commence. A CHMP opinion is anticipated in the first half of 2022.